(Beijing / Shanghai Comprehensive News) At the time of China's adjustment of crown disease epidemic prevention and control strategies, some Chinese medical experts proposed that crown diseases have been mutated into another disease."" ".
According to the Beijing Daily, the Chinese Medicine Society of Chinese Medicine Infection Branch held an expert consensus meeting on Monday (December 5), and learned that the chairman of the infection branch Gu Xiaohong said that she and a dozen deputy chairmen reachedThe above consensus.
Gu Xiaohong, who is also the secretary of the Party Committee of Beijing University of Traditional Chinese Medicine, is also an expert in the research group of the State Council's new crown pneumonia joint prevention joint control mechanism.She said that when the new crown virus appeared at the end of 2019, the use of "pneumonia" was not very accurate: "Because there are still a considerable number of people who do not have pneumonia, it may also cause liver function and renal function damage. After three years, after three yearsFrom the perspective of experts, the virus has been mutated into another disease, which rarely causes lung infection. It mainly infected the respiratory tract, but at the same time, it is extremely contagious. We call it a new coronary virus infectious disease. "
Some experts in Guangdong proposed to call the virus a cold, but Gu Xiaohong believed that the "cold" did not emphasize contagious, and the naming highlighted contagious, which would help the public to protect the public.
According to the 21st century economic reports, a number of domestic coronary vaccines in China have been approved for emergency use this week, and they have made four companies, including Shenzhou cells, Wantai Biology, Sanya Biology, and Wesk Bio.
Among them, the rhinoplastic virus carrier vaccine developed by Wantai Biological and Xiamen University and Hong Kong University is the first rhinoplasty vaccine in China to be approved for emergency use. It is also the earliest clinical trial and so far in the world.The only mucosal immunotherapy vaccine that verified safety and broad -spectrum validity in the third phase of clinical trials.
However, industry insiders said that with reference to previous experience, companies from obtained emergency use to push to the market for grass -roots use, and the middle needs to undergo the guidance and access process of relevant government agencies.As of now, 13 domestic vaccines have been approved in China, but there are no MRNA vaccines.
